Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 1,351 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestive System Abnormalities Clear all
Completed Phase 1 Interventional Results available

Durability of Hypertonic Saline for Enhancing Mucociliary Clearance in Cystic Fibrosis

NCT01094704
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
sodium chloride (7%)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 21, 2012 · Synced Oct 30, 2026, 10:11 AM EDT
Completed Not applicable Interventional Results available

Intrapulmonary Percussive Ventilation for Sputum Induction in Adults With Cystic Fibrosis

NCT06311292
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Volara System
Device
Lead sponsor
Daniel J. Weiner
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 30, 2026, 10:11 AM EDT
Withdrawn No phase listed Observational

Transfer Impedance in Cystic Fibrosis

NCT00743158
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 30, 2026, 10:11 AM EDT
Completed Phase 3 Interventional Results available

Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda

NCT00599326
View directory record Official record
Conditions
Porphyria Cutanea Tarda
Interventions
Deferasirox
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 30, 2026, 10:11 AM EDT
Not listed No phase listed Observational

Management of Esophagitis Following Repair of Esophageal Atresia

NCT03619408
View directory record Official record
Conditions
Esophageal Atresia, Esophagitis
Interventions
Antacids
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
30 Days to 17 Years
Enrollment
50 participants
Timeline
2019 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2021 · Synced Oct 30, 2026, 10:11 AM EDT
Recruiting Phase 2 Interventional

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic Fibrosis

NCT06429176
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
SPL84, Placebo
Drug · Other
Lead sponsor
SpliSense Ltd.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Denver, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 30, 2026, 10:11 AM EDT
Completed Phase 2 Interventional

Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs

NCT00198289
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Aurexis® (tefibazumab)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
7 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 30, 2026, 10:11 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members

NCT02194387
View directory record Official record
Conditions
Body Mass Index 25 or Greater, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Breast Carcinoma, Cancer Survivor, Chronic Lymphocytic Leukemia, Fatigue, Health Status Unknown, Lynch Syndrome, Ovarian Carcinoma, Overweight
Interventions
Dietary Intervention, Internet-Based Intervention, Laboratory Biomarker Analysis, Questionnaire Administration, Telephone-Based Intervention
Dietary Supplement · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 30, 2026, 10:11 AM EDT
Enrolling by invitation Not applicable Interventional

Strategy for Management of Patients With Hereditary Cancer Syndromes (HCS) in a Rural Environment

NCT07381985
View directory record Official record
Conditions
Hereditary Cancer Syndromes, BRCA1 Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome
Interventions
Longitudinal Cancer Genetics Follow-Up Program
Behavioral
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 30, 2026, 10:11 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum

NCT07811193
View directory record Official record
Conditions
Colorectal Adenocarcinoma
Interventions
VVD-133214, Pembrolizumab
Drug
Lead sponsor
Vividion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Tucson, Arizona • Ann Arbor, Michigan • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 30, 2026, 10:11 AM EDT
Completed Early Phase 1 Interventional

Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin Deficiency

NCT00377416
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
rAAV2-CB-hAAT Gene Vector
Genetic
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2020
U.S. locations
2
States / cities
Gainesville, Florida • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 10, 2020 · Synced Oct 30, 2026, 10:11 AM EDT
Completed Phase 3 Interventional

Cinacalcet to Treat Familial Primary Hyperparathyroidism

NCT00325104
View directory record Official record
Conditions
Hypercalcemia, Familial Primary Hyperparathyroidism
Interventions
Parathyroid hormone testing, Serum calcium testing
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 30, 2026, 10:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Mouthwash Study of Pioglitazone and Simvastatin in Healthy Volunteers

NCT00531882
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Pioglitazone, Simvastatin, Ibuprofen
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 30, 2026, 10:11 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

NCT05033080
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA, Placebo (matched to VX-121/TEZ/D-IVA), Placebo (matched to ELX/TEZ/IVA), Placebo (matched to IVA)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
69
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 61 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 30, 2026, 10:11 AM EDT
Completed Phase 1 Interventional Results available

A Phase I Study to Evaluate the Oral Absorption of Nepadutant in Infants

NCT00655083
View directory record Official record
Conditions
Infantile Colic, Infantile Functional Gastrointestinal Disorders
Interventions
Nepadutant
Drug
Lead sponsor
Menarini Group
Industry
Eligibility
6 Weeks to 24 Weeks
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Little Rock, Arkansas • Louisville, Kentucky • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 17, 2011 · Synced Oct 30, 2026, 10:11 AM EDT
Completed Phase 1 Interventional

Repeatability and Response Study of Absorptive Clearance Scans

NCT01887197
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Absorptive clearance scan, inhaled hypertonic saline (7%), mannitol inhalation powder
Other · Drug
Lead sponsor
Tim Corcoran
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Oct 30, 2026, 10:11 AM EDT
Completed Not applicable Interventional

Esophageal Atresia: a Natural Experiment of the Effects of Oral Inoculation on the Gut Microbiome

NCT04901546
View directory record Official record
Conditions
Esophageal Atresia
Interventions
Patient's own saliva
Other
Lead sponsor
Stanford University
Other
Eligibility
Up to 3 Months
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 30, 2026, 10:11 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)

NCT06792500
View directory record Official record
Conditions
MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)
Interventions
Glycerol Tributyrate
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 30, 2026, 10:11 AM EDT
Withdrawn Phase 2 Interventional

Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations

NCT05641298
View directory record Official record
Conditions
Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
Interventions
Sodium Fusidate, Placebo
Drug
Lead sponsor
Aceragen
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
25
States / cities
Gainesville, Florida • Orlando, Florida • Pensacola, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 30, 2026, 10:11 AM EDT
Completed Phase 3 Interventional Results available

Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

NCT00510484
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Pancrelipase Delayed Release, Placebo Comparator
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
19
States / cities
Long Beach, California • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2010 · Synced Oct 30, 2026, 10:11 AM EDT
Terminated Phase 3 Interventional Results available

Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria

NCT03219164
View directory record Official record
Conditions
Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization, Cystic Fibrosis
Interventions
AZLI, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
3 Months to 18 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
12
States / cities
San Francisco, California • Washington D.C., District of Columbia • St. Petersburg, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 30, 2026, 10:11 AM EDT
Terminated No phase listed Observational

A Multi-Center Study of the CF Quantum® Sweat Test System

NCT02404714
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Iontophoresis sweat test
Device
Lead sponsor
Polychrome Medical, Inc.
Industry
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Birmingham, Alabama • Chicago, Illinois • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 30, 2026, 10:11 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma

NCT04604132
View directory record Official record
Conditions
Gastric Adenocarcinoma
Interventions
Derazantinib, Derazantinib-paclitaxel-ramucirumab combination
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Orlando, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 30, 2026, 10:11 AM EDT
Completed Phase 1 Interventional Results available

Viral Kinetics in HCV Clearance in Subjects With Hemophilia

NCT01704521
View directory record Official record
Conditions
Chronic Hepatitis C, Hemophilia
Interventions
PegInterferon, Ribavirin, Telaprevir
Drug
Lead sponsor
Kenneth Sherman
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Oct 30, 2026, 10:11 AM EDT